The Technical Analyst
Calliditas Therapeutics [CALT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Calliditas Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.57% $19.50
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 523.32 mill |
| EPS: | -1.610 |
| P/E: | -12.11 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 26.84 mill |
| Avg Daily Volume: | 0.0070 mill |
| RATING 2024-04-25 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -12.11 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.06x |
| Company: PE -12.11 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 18.63 - 20.37 ( +/- 4.46%) |
| ATR Model: 14 days |
Forecast:
16:00 - $19.50
Live Trading Signals (every 1 min)
Forecast
1: 15:42 - $19.78
Forecast 2: 16:00 - $19.50
Forecast 3: 16:00 - $19.50
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $19.50 (1.57% ) |
| Volume | 0.0038 mill |
| Avg. Vol. | 0.0070 mill |
| % of Avg. Vol | 54.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CALT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CALT
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Last 10 Buy Signals
Latest Press Releases
2024-04-24 13:26:00 - Press Release
Calliditas Therapeutics' 2023 Annual Report Published
Stockholm , april 24, 2024 /prnewswire/ -- calliditas therapeutics ab (nasdaq: calt), (nasdaq stockholm: caltx) ("calliditas") today announces that the annual report for 2023 now is available at the company's website: www.calliditas.com for further information, please contact: Åsa hillsten, head of ir & sustainability, calliditastel.: +46 76 403 35 43, email: asa.hillsten@calliditas.com this information is information that calliditas therapeutics ab is obliged to make public pursuant to the securities markets act.
2024-04-24 03:26:00 - Press Release
Calliditas Announces Positive Nefigard Open Label Extension Results
Stockholm , april 24, 2024 /prnewswire/ -- calliditas therapeutics ab (nasdaq: calt), (nasdaq stockholm: caltx) ("calliditas") today announced that the global open-label extension (ole) study to the phase 3 nefigard study showed a treatment response consistent with the nefigard study across endpoints of urine protein to creatinine ration (upcr) and estimated glomerular filtration rate (egfr) at 9 months across all igan patients, including those who had previously received nefecon in the nefigard study. nefigard was a global, phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of nefecon 16 mg once daily vs placebo in adult patients with primary igan as an addition to optimized rasi therapy.
2024-04-18 07:10:00 - Press Release
Calliditas Therapeutics Presents Additional Data Analyses From The Phase 3 Neflgard Trial Of Nefecon In Primary Iga Nephropathy At The Isn World Congress Of Nephrology 2024
Stockholm , april 18, 2024 /prnewswire/ -- calliditas therapeutics ab (nasdaq: calt) (nasdaq stockholm: caltx) ("calliditas"), today announced additional data analyses from the 2-year phase 3 neflgard trial evaluating nefecon (tarpeyo® (budesonide) delayed-release capsules/kinpeygo®) in patients with iga nephropathy (igan), were presented at the isn world congress of nephrology in buenos aires, argentina on april 13-16, 2024. "we were pleased to share additional analyses from the 2-year phase 3 neflgard trial of nefecon in igan at this year's world congress of nephrology," said richard philipson, chief medical officer of calliditas.
2024-04-08 08:32:00 - Press Release
Calliditas Therapeutics To Present Nefecon Data At The Isn World Congress Of Nephrology April 13 - 16 In Buenos Aires
Stockholm , april 8, 2024 /prnewswire/ -- calliditas therapeutics ab (nasdaq: calt) (nasdaq stockholm: caltx) ("calliditas"), today announced upcoming data presentations, as well as a sponsored symposium at the international society of nephrology's world congress of nephrology. the isn world congress of nephrology will be held in buenos aires, argentina april 13-16, 2024.
2024-04-08 03:22:00 - Press Release
Calliditas Receives Notice Of Allowance For United States Patent Application Covering Setanaxib In Cancer Treatment
Stockholm , april 8, 2024 /prnewswire/ -- calliditas therapeutics ab (nasdaq: calt) (nasdaq stockholm: caltx) ("calliditas") today announced that the company has received a notice of allowance from the united states patent and trademark office (uspto) for patent application no. 16/760,910 entitled "use of nox inhibitors for treatment of cancer".
Latest News
2024-04-08 08:32:00 - PRNewsWire
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
STOCKHOLM , April 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations, as well as a sponsored symposium at the International Society of Nephrology's World Congress of Nephrology. The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
2024-03-01 07:39:00 - PRNewsWire
Calliditas Therapeutics to Attend Investor Conferences in March
STOCKHOLM , March 1, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Renee Aguiar-Lucander, CEO of Calliditas will participate in the following March 2024 conferences. Carnegie Healthcare Seminar, Wednesday, March 6, 2024.
2024-01-07 11:05:00 - PRNewsWire
Calliditas to present at JP Morgan Healthcare Conference
STOCKHOLM , Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California.
2023-12-21 08:06:00 - Market Watch
Calliditas Therapeutics stock jumps as kidney treatment gets FDA approval
Calliditas Therapeutics AB's American depositary receipts CALT, +6.84% jumped 15% premarket on Thursday after the company said late Wednesday that its kidney treatment Tarpeyo received full approval from the U.S. Food and Drug Administration. The agency approved the drug to reduce the loss of kidney function in adults with primary immunoglobin A nephropathy, or IgAN, a disease in which protein builds up in the kidneys, causing inflammation and damaging the kidneys' ability to filter waste from the blood.
2023-12-20 17:45:00 - Reuters
US FDA approves Sweden-based Calliditas' kidney disease drug
The U.S. Food and Drug Administration (FDA) granted full approval to Swedish drugmaker Calliditas Therapeutics' drug to treat rare kidney disease IgA Nephropathy (IgAN), the company said on Wednesday.
2023-11-27 18:40:01 - Seeking Alpha
Calliditas Therapeutics: Undervalued Rare Disease Commercial Stage Biotech (Maintaining Buy)
Q3 2023 sales for Calliditas Therapeutics' flagship drug Tarpeyo fell short of expectations but showed incremental growth. Despite challenges, the number of prescribers and improvements in market access for Tarpeyo indicate long-term success. 2024 is expected to be an inflection point for the company, with full approval of Tarpeyo and positive Phase III data.
2023-10-19 03:58:00 - PRNewsWire
Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
STOCKHOLM , Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023. Investigators will be presenting additional analyses of the Phase 3 NefIgArd study's 2-year data with Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) for the treatment of Primary IgA nephropathy (IgAN).
2023-09-22 05:16:06 - Zacks Investment Research
Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?
Calliditas Therapeutics AB Sponsored ADR (CALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2023-09-21 14:32:43 - The Motley Fool
Why Shares of Calliditas Therapeutics Are Rising Thursday
Calliditas' lead therapy is Tarpeyo, which has accelerated approval from the FDA to fight a rare autoimmune disease affecting the kidney. The company plans to release updated phase 3 trial information at a conference next week.
2023-09-03 04:26:46 - Seeking Alpha
Calliditas: Q2 Earnings De-Risk This Biotech Play, 2024 Expected To Be Inflection Point
Calliditas Therapeutics downgrades Tarpeyo sales guidance due to slower-than-expected sales growth and market access challenges. Potential growth drivers include full-label expansion of Tarpeyo and addressing the educational gap about the duration of treatment. Delays in the TRANSFORM trial of setanaxib pose risks, but management remains optimistic about potential partnering discussions.